First-in-human Phase 1/2 clinical trial of iPSC derived islet-like clusters in combination with Cell Pouch™ device for the treatment of patients with T1D and severe hypoglycemia
Latest Information Update: 13 Oct 2023
At a glance
- Drugs IPSC-based-beta-cell-replacement-therapy-Evotec/Sernova (Primary)
- Indications Hypoglycaemia; Type 1 diabetes mellitus
- Focus Adverse reactions; First in man
- 11 Oct 2023 Status changed from planning to recruiting.
- 11 Oct 2023 According to a Sernova Corp media release, new data from this study will be presented at International Pancreas and Islet Transplant Association (IPITA) on Thursday, October 26, 2023
- 13 Jan 2023 New trial record